Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) General Information
Description
License for late-phase 3 oncology immunotherapy. The asset is a license for a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor-binding domain with diphtheria toxin fragments and is used for the treatment of cutaneous t-cell lymphoma and other cancer indications
Contact Information
Corporate Office
- 8-2-337, Road Number Three
- Banjara Hills
- Hyderabad, Telangana 500034
- India
Corporate Office
- 8-2-337, Road Number Three
- Banjara Hills
- Hyderabad, Telangana 500034
- India
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) FAQs
-
Where is Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) headquartered?
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) is headquartered in Hyderabad, India.
-
What industry is Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) in?
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)’s primary industry is Buildings and Property.
-
Is Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) a private or public company?
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) is a Private company.
-
What is the current valuation of Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)?
The current valuation of Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) is .
-
What is Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)’s current revenue?
The current revenue for Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) is .
-
Who are Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)’s investors?
Dr. Reddy's has invested in Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777).
-
When was Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) acquired?
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) was acquired on 07-Sep-2021.
-
Who acquired Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777)?
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) was acquired by Citius Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process